These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 27418594)

  • 1. Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation: Concordance With Clinical Outcomes.
    Tardif JC; Rhainds D; Brodeur M; Feroz Zada Y; Fouodjio R; Provost S; Boulé M; Alem S; Grégoire JC; L'Allier PL; Ibrahim R; Guertin MC; Mongrain I; Olsson AG; Schwartz GG; Rhéaume E; Dubé MP
    Circ Cardiovasc Genet; 2016 Aug; 9(4):340-8. PubMed ID: 27418594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CETP: Pharmacogenomics-Based Response to the CETP Inhibitor Dalcetrapib.
    Tardif JC; Rhainds D; Rhéaume E; Dubé MP
    Arterioscler Thromb Vasc Biol; 2017 Mar; 37(3):396-400. PubMed ID: 28126828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib.
    Tardif JC; Rhéaume E; Lemieux Perreault LP; Grégoire JC; Feroz Zada Y; Asselin G; Provost S; Barhdadi A; Rhainds D; L'Allier PL; Ibrahim R; Upmanyu R; Niesor EJ; Benghozi R; Suchankova G; Laghrissi-Thode F; Guertin MC; Olsson AG; Mongrain I; Schwartz GG; Dubé MP
    Circ Cardiovasc Genet; 2015 Apr; 8(2):372-82. PubMed ID: 25583994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of dalcetrapib in patients with a recent acute coronary syndrome.
    Schwartz GG; Olsson AG; Abt M; Ballantyne CM; Barter PJ; Brumm J; Chaitman BR; Holme IM; Kallend D; Leiter LA; Leitersdorf E; McMurray JJ; Mundl H; Nicholls SJ; Shah PK; Tardif JC; Wright RS;
    N Engl J Med; 2012 Nov; 367(22):2089-99. PubMed ID: 23126252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial.
    Lüscher TF; Taddei S; Kaski JC; Jukema JW; Kallend D; Münzel T; Kastelein JJ; Deanfield JE;
    Eur Heart J; 2012 Apr; 33(7):857-65. PubMed ID: 22345126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study design of Dal-GenE, a pharmacogenetic trial targeting reduction of cardiovascular events with dalcetrapib.
    Tardif JC; Dubé MP; Pfeffer MA; Waters DD; Koenig W; Maggioni AP; McMurray JJV; Mooser V; White HD; Heinonen T; Black DM; Guertin MC;
    Am Heart J; 2020 Apr; 222():157-165. PubMed ID: 32087417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of Adenylate Cyclase 9 in the Pharmacogenomic Response to Dalcetrapib: Clinical Paradigm and Molecular Mechanisms in Precision Cardiovascular Medicine.
    Rhainds D; Packard CJ; Brodeur MR; Niesor EJ; Sacks FM; Jukema JW; Wright RS; Waters DD; Heinonen T; Black DM; Laghrissi-Thode F; Dubé MP; Pfeffer MA; Tardif JC
    Circ Genom Precis Med; 2021 Apr; 14(2):e003219. PubMed ID: 33794646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advancing Beyond Failed High-density Lipoprotein Clinical Trials to Pharmacogenetic Studies of ADCY9 and Cholesterol Ester Transfer Protein Inhibition.
    Black DM; Miller M; Heinonen TM; Zhang G
    J Cardiovasc Pharmacol; 2021 Oct; 78(4):496-500. PubMed ID: 34173811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases.
    Shinkai H
    Vasc Health Risk Manag; 2012; 8():323-31. PubMed ID: 22661899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of dyslipidemia - is here still place for CETP-inhibitors?].
    Murín J; Pernický M; Kiňová S
    Vnitr Lek; 2016; 62(10):789-794. PubMed ID: 27900865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammatory and Cholesterol Risk in the FOURIER Trial.
    Bohula EA; Giugliano RP; Leiter LA; Verma S; Park JG; Sever PS; Lira Pineda A; Honarpour N; Wang H; Murphy SA; Keech A; Pedersen TR; Sabatine MS
    Circulation; 2018 Jul; 138(2):131-140. PubMed ID: 29530884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetics-guided dalcetrapib therapy after an acute coronary syndrome: the dal-GenE trial.
    Tardif JC; Pfeffer MA; Kouz S; Koenig W; Maggioni AP; McMurray JJV; Mooser V; Waters DD; Grégoire JC; L'Allier PL; Wouter Jukema J; White HD; Heinonen T; Black DM; Laghrissi-Thode F; Levesque S; Guertin MC; Dubé MP;
    Eur Heart J; 2022 Oct; 43(39):3947-3956. PubMed ID: 35856777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trial.
    Ray KK; Ditmarsch M; Kallend D; Niesor EJ; Suchankova G; Upmanyu R; Anzures-Cabrera J; Lehnert V; Pauly-Evers M; Holme I; Štásek J; van Hessen MW; Jones P;
    Eur Heart J; 2014 Jul; 35(27):1792-800. PubMed ID: 24639426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ADCY9 Genetic Variants and Cardiovascular Outcomes With Evacetrapib in Patients With High-Risk Vascular Disease: A Nested Case-Control Study.
    Nissen SE; Pillai SG; Nicholls SJ; Wolski K; Riesmeyer JS; Weerakkody GJ; Foster WM; McErlean E; Li L; Bhatnagar P; Ruotolo G; Lincoff AM
    JAMA Cardiol; 2018 May; 3(5):401-408. PubMed ID: 29525816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dalcetrapib: a review of Phase II data.
    Robinson JG
    Expert Opin Investig Drugs; 2010 Jun; 19(6):795-805. PubMed ID: 20465364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of dalcetrapib in type 2 diabetes mellitus and/or metabolic syndrome patients, at high cardiovascular disease risk.
    Stalenhoef AF; Davidson MH; Robinson JG; Burgess T; Duttlinger-Maddux R; Kallend D; Goldberg AC; Bays H
    Diabetes Obes Metab; 2012 Jan; 14(1):30-9. PubMed ID: 21819519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dalcetrapib , a cholesteryl ester transfer protein modulator.
    Hooper AJ; Burnett JR
    Expert Opin Investig Drugs; 2012 Sep; 21(9):1427-32. PubMed ID: 22725099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and tolerability of dalcetrapib.
    Stein EA; Stroes ES; Steiner G; Buckley BM; Capponi AM; Burgess T; Niesor EJ; Kallend D; Kastelein JJ
    Am J Cardiol; 2009 Jul; 104(1):82-91. PubMed ID: 19576325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the cholesteryl ester transfer protein inhibitor, TA-8995, on cholesterol efflux capacity and high-density lipoprotein particle subclasses.
    van Capelleveen JC; Kastelein JJ; Zwinderman AH; van Deventer SJ; Collins HL; Adelman SJ; Round P; Ford J; Rader DJ; Hovingh GK
    J Clin Lipidol; 2016; 10(5):1137-1144.e3. PubMed ID: 27678430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CETP inhibition in perspective.
    Stock J
    Atherosclerosis; 2012 Feb; 220(2):325-8. PubMed ID: 22079329
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.